La Roche-Posay is launching in March its new Rosaliac AR Intense Localized Redness Intensive Care, which reduces visible redness and irritation, and is suitable for rosacea-prone skin.
More than 200 drugs are under development in the United States for treating skin diseases, according to the country’s largest pharmaceutical industry trade group.